Asahi Kasei tops up Feldan Therapeutics' Series A to $13.8 mln

Feldan Therapeutics, a Québec City-based pre-clinical biotechnology company, has raised $1.3 million in financing from Asahi Kasei Corporate Venture Capital, the investment arm of Japanese conglomerate Asahi Kasei Corp. The investment increases Feldan's Series A financing to $13.8 million. In September, the company secured an initial $12.5 million led by South Korea's GC and joined by Stonebridge Ventures, Anges Québec and Anges Québec Capital. Founded in 2007, Feldan is developing a pipeline of therapeutic applications based on the Feldan Shuttle, its peptide intracellular delivery technology.

CanadaNorth AmericaBriefs